LY518674 structure
|
Common Name | LY518674 | ||
---|---|---|---|---|
CAS Number | 425671-29-0 | Molecular Weight | 409.47800 | |
Density | 1.21g/cm3 | Boiling Point | 575.852ºC at 760 mmHg | |
Molecular Formula | C23H27N3O4 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 302.065ºC |
Use of LY518674LY518674 is a potent, selective PPARα antagonist, with an EC50 of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis[1][2][3]. |
Name | 2-[4-[3-[2,5-dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxy]-2-methylpropanoic acid |
---|---|
Synonym | More Synonyms |
Description | LY518674 is a potent, selective PPARα antagonist, with an EC50 of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis[1][2][3]. |
---|---|
Related Catalog | |
Target |
EC50: 42 nM (human PPARα)[1] |
In Vivo | LY518674 reduces triglycerides and increased HDL-C in vivo[2]. LY518674 substantially increases apolipoprotein A-I (apoA-I) turnover without major impact on steady-state levels of apoA-I or high-density lipoprotein-cholesterol (HDL-C) [3]. |
References |
Density | 1.21g/cm3 |
---|---|
Boiling Point | 575.852ºC at 760 mmHg |
Molecular Formula | C23H27N3O4 |
Molecular Weight | 409.47800 |
Flash Point | 302.065ºC |
Exact Mass | 409.20000 |
PSA | 97.21000 |
LogP | 3.34540 |
Index of Refraction | 1.594 |
Storage condition | 2-8°C |
2-Methyl-2-[4-[3-[1-(4-Methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid |
Propanoic acid,2-[4-[3-[2,5-dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxy]-2-methyl |
2-[4-[3-[4,5-dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxy]-2-methylpropanoic acid |
2-[4-[3-[2,5-dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxy]-2-methyl-propanoic acid |